KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) Enterprise Value (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Enterprise Value for 8 consecutive years, with -$220.8 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value rose 0.78% to -$220.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$220.8 million through Dec 2025, up 0.78% year-over-year, with the annual reading at -$220.8 million for FY2025, 0.78% up from the prior year.
  • Enterprise Value hit -$220.8 million in Q4 2025 for Adaptive Biotechnologies, down from -$213.0 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$193.6 million in Q1 2025 to a low of -$714.1 million in Q1 2021.
  • Historically, Enterprise Value has averaged -$365.1 million across 5 years, with a median of -$358.2 million in 2021.
  • Biggest five-year swings in Enterprise Value: soared 50.3% in 2021 and later plummeted 41.17% in 2022.
  • Year by year, Enterprise Value stood at -$353.0 million in 2021, then tumbled by 41.17% to -$498.3 million in 2022, then surged by 30.45% to -$346.5 million in 2023, then surged by 35.79% to -$222.5 million in 2024, then grew by 0.78% to -$220.8 million in 2025.
  • Business Quant data shows Enterprise Value for ADPT at -$220.8 million in Q4 2025, -$213.0 million in Q3 2025, and -$198.1 million in Q2 2025.